查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肝纤维化治疗市场：按治疗类型、按疾病状态、按分销渠道、按地区 - 规模、份额、前景、机会分析，2022-2030
市场调查报告书
商品编码
1110242

肝纤维化治疗市场：按治疗类型、按疾病状态、按分销渠道、按地区 - 规模、份额、前景、机会分析，2022-2030

Liver Fibrosis Treatment Market, by Treatment Type, by Condition, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3个工作天内

价格
简介目录

肝纤维化，即胶原蛋白等细胞外基质蛋白的过度积累，发生在大多数类型的慢性肝病中。晚期肝纤维化导致肝硬化、肝功能衰竭和门静脉高压症，通常需要肝移植。肝纤维化的特征是肝臟反復或持续性损伤，导致肝臟瘢痕组织数量异常。纤维化没有主观症状，但随着瘢痕形成的进展，肝硬化发展，症状进一步进展。为了确定慢性肝病的严重程度，医疗保健从业者将进行血液检查、影像学检查，并在必要时进行肝活检。对于肝纤维化的可能治疗方法，医疗专业人员通常专注于治疗原因以阻止或减缓肝臟进一步瘢痕形成，从而改善病情。肝纤维化的治疗包括使用抗病毒药物、去除/溶解胆管阻塞、改变生活方式（例如减少酒精摄入）、管理肥胖/超重以及非酒精性脂肪肝患者的血糖水平。脂质水平。

市场动态

在预测期内，随着高脂饮食人口的增加，非酒精性脂肪性肝炎 (NASH) 的主要患病率预计会增加。随着主要参与者专注于开发这些疾病的治疗方法，肥胖和糖尿病流行、肝纤维化和 NASH 的增加预计将推动市场增长。例如，2022 年 4 月，根据美国国家生物技术信息中心的数据，过去十年美国 NASH 的患病率显着增加。这可能不仅与提高对该疾病的认识有关，还与增加的风险因素有关。 2021年NASH病例的性别分布为女性54.1%，男性45.9%。专家估计，大约 24% 的美国成年人患有非酒精性脂肪肝 (NAFLD)，大约 1.5% 至 6.5% 患有 NASH。非酒精性脂肪性肝病 (NAFLD) 会影响 20% 至 30% 的从单纯脂肪进展为非酒精性脂肪性肝炎 (NASH) 的人。另外 20% 至 30% 进展为更晚期的非酒精性脂肪性肝炎 (NASH) 纤维化，其最后阶段是非酒精性脂肪性肝炎 (NASH) 肝硬化。

本研究的主要特点

  • 本报告对全球肝纤维化治疗市场进行了深入分析，揭示了以 2021 年为基准年的预测期内（2022-2030 年）的市场规模（十亿美元）和復合年增长率 (CAGR) . %) 提供。
  • 解释不同细分市场的潜在收入机会，并描述该市场具有吸引力的投资建议矩阵。
  • 该研究还提供了有关市场驱动因素、抑制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
  • 根据公司亮点、产品组合、关键亮点、财务业绩和战略等参数，对全球肝纤维化治疗市场的主要参与者进行概况介绍。
  • 本研究涵盖的主要公司包括 Gilead Sciences, Inc.、Merck & Co., Inc.、Bristol-Myers Squibb、Johnson and Johnson、Novartis AG、Vertex Pharmaceuticals Incorporated、Pfizer Inc.、FibroGen, Inc.。 , 和 Pharmaxis 有限公司
  • 本报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。奖品
  • 全球肝纤维化治疗市场报告迎合了该行业的各种利益相关者，包括投资者和供应商、产品製造商、分销商、新进入者和财务分析师。
  • 通过已用于分析全球肝纤维化治疗市场的各种战略矩阵，利益相关者可以促进决策。

内容

第 1 章目的和先决条件

  • 调查目的
  • 先决条件
  • 缩写说明

第 2 章市场展望

  • 举报内容
    • 市场定义和范围
  • 执行摘要
    • 市场快照：按治疗类型
    • 市场快照：按疾病状态
    • 市场快照：按销售渠道
    • 市场概况：按地区划分
  • 连贯的机会图 (COM)

第 3 章市场动态、监管和趋势分析

  • 市场动态
    • 驱动程序
    • 约束因素
    • 市场机会
  • 影响分析
  • 市场趋势
  • 近期趋势
  • 收购和合作方案
  • 技术概述
  • 监管场景
  • 药物管线分析
  • 价格分析
  • PEST 分析

第 4 章全球肝纤维化药物市场 - 冠状病毒 (COVID-19) 大流行的影响

  • 整体影响
  • 政府举措
  • COVID-19 对市场的影响

第 5 章全球肝纤维化药物市场，按治疗类型，2017-2030 年

  • 过氧化物□体增殖物激活受体 (PPAR)-α 激动剂
  • ACE抑製剂
  • 益肝药
  • 其他

第 6 章按疾病状态分列的肝纤维化药物全球市场，2017-2030 年

  • 慢性肝病
  • 丙型肝炎
  • 非酒精性脂肪性肝炎

第 7 章按分销渠道分列的肝纤维化药物全球市场：2017-2030

  • 医院
  • 专科诊所
  • 其他

第 8 章全球肝纤维化药物市场：按地区分列，2017-2030

  • 北美
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地区
  • 欧洲
  • 英国
  • 德国
  • 意大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 东盟
  • 澳大利亚
  • 韩国
  • 其他亚太地区
  • 中东
  • 海合会
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中非
  • 南非

第 9 章竞争格局

  • 热图分析
  • 市场份额分析
  • 公司简介
    • Gilead Sciences, Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb
    • Johnson and Johnson
    • Novartis AG
    • Vertex Pharmaceuticals Incorporated
    • Pfizer Inc.
    • FibroGen, Inc.
    • Pharmaxis Limited

第10章 章节

  • 参考文献
  • 调查手法介绍
简介目录
Product Code: CMI2320

Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. Liver fibrosis is characterized by repeated or continuous damage to liver resulting in an abnormally large amount of scar tissue in the liver. Fibrosis does not show any symptoms, however severe scarring results into cirrhosis, which further leads to cause symptoms. To detect the severity of chronic liver disease, healthcare professionals conduct blood and imaging test, followed by liver biopsy, if required. In the possible treatment options for liver fibrosis, healthcare professionals focus on treating the cause, which often stops and slows down further scarring of liver and results in improvement of the condition. The possible treatment options for liver fibrosis include use of antiviral drugs, removal or dissolution of a blockage in the bile ducts, lifestyle changes such as lower consumption of alcohol, control regime for obesity and overweight, and controlling blood sugar & lipid levels in people with nonalcoholic fatty liver.

Market Dynamics

The underlining prevalence cases of Non-alcoholic Steatohepatitis (NASH) are expected to increase over the forecast period with increasing amount of population consuming high fat diet. Increasing obesity and diabetes epidemics, liver fibrosis, and NASH are expected to drive market growth, as key players are focused on developing treatment for these disorders. For instance, in April 2022, according to National Center for Biotechnology Information, the prevalence of NASH has significantly increased in the U.S. in the last decade. This is likely related to the increased prevalence of risk factors as well as increased awareness of the disease. The proportion of patients with NASH by gender was 54.1% female verses 45.9% male in 2021. Experts estimate about 24% of U.S. adults have Non-alcoholic fatty liver disease (NAFLD) and about 1.5% to 6.5% of U.S. adults have NASH. Non-alcoholic fatty liver disease (NAFLD) states as simple fat, which impacts on 20% to 30% of those individuals who progress to nonalcoholic steatohepatitis (NASH). Another 20% to 30% of individual's progress to more advanced Non-alcoholic Steatohepatitis (NASH) fibrosis, and the final stage is Non-alcoholic Steatohepatitis (NASH) cirrhosis.

Key features of the study:

  • This report provides an in-depth analysis of the global liver fibrosis treatment market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global liver fibrosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., and Pharmaxis Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global liver fibrosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liver fibrosis treatment market

Detailed Segmentation:

  • Global Liver Fibrosis Treatment, By Treatment Type :
    • Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
    • ACE Inhibitors
    • Hepatotropic Drug
    • Others
  • Global Liver Fibrosis Treatment, By Condition:
    • Chronic Liver Diseases
    • Hepatitis C
    • Nonalcoholic Steatohepatitis
  • Global Liver Fibrosis Treatment, By Distribution Channel:
    • Hospitals
    • Specialty Clinics
    • Others
  • Global Liver Fibrosis Treatment, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Gilead Sciences, Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Merck & Co., Inc.
    • Bristol-Myers Squibb
    • Johnson and Johnson
    • Novartis AG
    • Vertex Pharmaceuticals Incorporated
    • Pfizer Inc.
    • FibroGen, Inc.
    • Pharmaxis Limited

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Treatment Type
    • Market Snapshot, By Condition
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Developments
  • Acquisitions and Partnerships Scenario
  • Technology Overview
  • Regulatory Scenario
  • Drug Pipeline Analysis
  • Pricing Analysis
  • PEST Analysis

4. Global Liver Fibrosis Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Liver Fibrosis Treatment Market, By Treatment Type, 2017 - 2030, (US$ Billion)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • ACE Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Hepatotropic Drug
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

6. Global Liver Fibrosis Treatment Market, By Condition, 2017 - 2030, (US$ Billion)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Chronic Liver Disease
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Hepatitis C
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Nonalcoholic Steatohepatitis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

7. Global Liver Fibrosis Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Billion)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospitals
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Specialty Clinics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

8. Global Liver Fibrosis Treatment Market, By Region, 2017 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Condition, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Condition, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Condition, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Condition, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Condition, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Condition, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Billion)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
  • Company Profiles
    • Gilead Sciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Johnson and Johnson
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Vertex Pharmaceuticals Incorporated
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • FibroGen, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Pharmaxis Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact